PerkinElmerCEO說公司不會出售

PerkinElmer公司CEO：Rob Friel

　　“我們沒有打算出售公司，這不是什么我們在董事會層面講的事情。” 羅伯特弗里爾Robert Friel在路透社的獨家電話采訪中告訴記者。

　　弗里爾正對上周四彭博社的報告作出回應，彭博社報告說這家公司剛剛錯過了購買更大的診斷公司貝克曼.庫爾特（BEC.N），并正在和美國銀行工作，因為它決定是否尋求另一收購或把自己掛牌出售。

　　“我們不是與美國銀行工作，” 在賓夕法尼亞州參加一個家庭葬禮的弗里爾說，“關于我們現在將決定出售公司的想法不是基于事實的。”

　　上周四，PerkinElmer的股票跳漲7個百分點，其交易量超過平均交易量股的4倍。這促使弗里爾反擊上述報告，即使這意味著股價會降低。

　　“我認為在該情況下這可能是正確的做法，因為我懷疑，助長了今天交易量蓄積的因素不是真的。”

　　在數小時的盤后交易后，PerkinElmer股票部分回落，從紐約證券交易所收盤時的 $27.72回落到$26.99。

　　弗里爾拒絕評論關于PerkinElmer投標貝克曼收購直到最后一刻的報告——這是一宗比它以前的典型收購高許多倍的交易，會涉及到重大的債務處理。熟知該次招標的人士告訴路透社，PerkinElmer一直試圖購買Beckman。

　　丹納赫公司（DHR.N）最終以58億美元收購貝克曼，這幾乎是PerkinElmer年收入的近3倍。

　　當被問及他是否會考慮另一宗該規模的交易時，弗里爾說，“在大多數情況下，我們看到更大交易的風險有時會高于其潛在的好處。”

　　“像這種規模的交易，必須是我們真正感到會為我們的股東們創造顯著價值的，必須是極具有吸引力以至于我們感到我們真正需要好好看一看的。”他補充說。

　　PerkinElmer主要銷售科學儀器、醫療檢測設備和環境安全監控產品，在歷史上每年都進行幾次收購，規模在5000萬美元到1億美元之間。

　　弗里爾表示，公司正在關注較大的交易。

　　“我們傾向于先開始作一些比之前稍大一些規模的收購。我們獲得了一個渠道的伙伴，看起來很有趣，我們將會收購更多這些在幾百萬美元范圍的渠道。”他說。

　　“我們擁有大量的現金，因此我們有相當大的借貸能力，我們覺得自己有很好的財務狀況，可以走出去做些1~2億美元的收購，以擴充我們已有的能力。我覺得這就是你們將要從我們這里展望的未來。”弗里爾說。

　　他傾向于在診斷、試劑、服務和軟件領域進行收購，且有助于擴大公司的地理覆蓋范圍。

　　“我們公司的核心戰略在根本上是建立在更小規模的收購基礎上的。”

　　（Reporting by Bill Berkrot； Editing by Richard Chang）

相關報道：

PerkinElmer回應將可能被出售的傳聞

PerkinElmer 25美分錯失收購貝克曼庫爾特良機

參考英文原文：

Exclusive: PerkinElmer CEO says company not for sale

(Reuters) - PerkinElmer Inc's (PKI.N) chief executive said a report that the company was deciding whether to put itself up for sale was not based on fact and "completely not true."

"We are not putting the company up for sale. It's not anything we talked about at the board level," Robert Friel told Reuters in an exclusive telephone interview.

Friel was reacting to a Bloomberg report on Thursday that said the company had just missed out on buying much larger diagnostics company Beckman Coulter Inc (BEC.N) and was working with Bank of America as it decides whether to seek another acquisition or put itself up for sale.

"We are not working with Bank of America," said Friel, who was in Pennsylvania for a family funeral. "This thought that we would now decide to position the company for sale is not based in fact."

PerkinElmer's shares jumped 7 percent with more than four times the average volume of shares trading on Thursday, prompting Friel to knock down the report even if it meant sending the share price lower.

"I saw the (Bloomberg) article and when I saw the volume of our stock today I felt we really needed to address it," Friel said.

"In this case I think it's probably the right thing to do because what I suspect is what is fueling the volume of the stock today is just not true."

PerkinElmer shares did give back some of its gains in after-hours trading, falling to $26.99 from a New York Stock Exchange close at $27.72.

Friel declined to comment on the report that PerkinElmer was in the bidding for Beckman until the eleventh hour -- a deal that would have been many times larger that its typical acquisitions, and one that would have involved taking on significant debt. People familiar with the bidding told Reuters that PerkinElmer had been trying to buy Beckman.

Danaher Corp (DHR.N) eventually landed Beckman for $5.8 billion, nearly three times PerkinElmer's annual revenue.

Asked if he would consider pursuing another deal of that size, Friel said, "In most cases when we look at larger transactions the risk aspects of the deal can sometimes outweigh the potential benefits," Friel said.

"Something like that of that size would have to be a transaction that we felt really created significant value for our shareholders, that was something that was just so attractive that we felt we really needed to take a look at it," he added.

PerkinElmer, which sells scientific instruments, medical testing equipment and environmental safety monitoring products, has historically made several acquisitions each year in the $50 million to $100 million range.

Friel said the company was eyeing somewhat larger deals.

"Our preference would be to start doing a little bigger than that. We got a couple in the pipeline that look pretty interesting that would be more in the couple hundred million range," he said.

"We generate a lot of cash so we have fairly significant borrowing capacity, so we feel good about our financial position from the perspective of going out and doing these $100 to $200 million acquisitions to add to the capabilities of what we have. And I think that's what you'll see from us going forward," Friel said.

His preference would be acquisitions in the areas of diagnostics, reagents and services and software, and deals that would expand the company's geographic reach.

"The core strategy of the company is fundamentally based on smaller type bolt-on acquisitions," he said.

(Reporting by Bill Berkrot; Editing by Richard Chang)